News

A team of investigators are working on a simple test that may someday identify those who can stop therapy.

A partnership that includes BALANCED Media|Technology, the Retina Foundation of the Southwest and Southern Methodist University is seeking a patent for machine learning software for OCT images aids in identity progression and treatment options.

According to the company, biped.ai includes a comfortable and lightweight collar fitted with 3D cameras that continuously monitor a 170° field of view for the user detecting, tracking and predicting the trajectories of all surrounding elements a few seconds in advance.

Faricimab is the first and only FDA-approved medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Joshua Mali, MD, shares how the FDA-approved faricimab-svoa (Vabysmo, Genentech) will change the treatment landscape for wet AMD and DME.

Genentech’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

Genentech’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

With the addition of 7 new therapeutics, Théa will expand its presence in the U.S. market.

The new variant is described as a "subvariant" of the omicron variant and is closely related to omicron, though it has some different mutations.

A team of investigators at the University of California, Irvine have found that inhibiting ceramide accumulation in retina protects photoreceptors improves vision

Nanoscope Therapeutics has received IND clearance from the FDA to begin a Phase 2 trial of its Multi-Characteristic Opsin ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients.

A team of investigators at the RIKEN Center for Biosystems Dynamics Research in Japan have used a genetic modification to improve human-derived retina transplants grown in the lab.

The study reviews the outcomes following penetrating, closed trauma–related injuries.

The improvement became evident during an average time of 6 months.

The historic eye institute celebrates six decades of leadership in eye care research, education and clinical practice.

Organization makes a commitment to expand translational research acceleration program and fund career development award.

Research also highlights the top factors that lead to care, which can be used to improve parents' uptake of sight-saving surgery for their children.

Work by a team of investigators is shedding light on the severity for gene variants and establishing outcome measures for therapeutic trials.

According to the company, the protocol enhancement for the RETeval Device marks an important step in mitigating vision loss from glaucoma.

A team of investigators are working on a simple test that may someday identify those who can stop therapy.

Investigators find that successful outcomes may depend on the awareness of red-flag symptoms and signs.

According to investigators, patients implanted with diffractive multifocal IOLs had notable declines in the corrected distance visual acuity, distance corrected near VA, and near area of focus with aging

Across four studies, about half of eligible faricimab patients were able to go 4 months between treatments, and approximately three-quarters could be treated every 3 months or longer. Two papers published in The Lancet highlight one-year results.

The historic Eye Institute rings in 60 years of leadership in eye care research, education and clinical practice.

A study finds acceptable outcomes, vision, and microperimetry improvements at higher doses.

Renewed consumer interest in and demand for LASIK, SMILE, and other procedures are among the key drivers for 2021 performance.

According to the companies, the trial will evaluate the safety, tolerability, and immune response of the vaccine that can be administered as a primary shot and a booster.

This Bascom Palmer Eye Institute 2-day virtual scientific program promises a distinguished international faculty who will share the latest developments in imaging, translational research, and clinical trials as well as the impact these advances will have on clinical ophthalmology.